Subscribe
Subscribe

Biomedical/pharma

Biomedical/pharma, Neurology

Antwerp Researcher Rosa Rademakers Wins ‘Oscar of Science’ for Dementia and ALS Discovery

Antwerp researcher Rosa Rademakers has won the Breakthrough Prize in the US — one of the world’s most prestigious science awards. Rademakers received the prize and more than 2.5 million euros for her groundbreaking discovery that a rare genetic mutation plays a key role in both frontotemporal dementia and ALS.

Europe’s Life Sciences Paradox: Strong Science, Weak Scale?

Europe has long positioned itself as a global leader in life sciences. With world-class research institutions and a steady pipeline of scientific breakthroughs, that claim is well founded. But at the heart of the ecosystem, there is a growing disconnect. Is Europe equipped to build and retain globally competitive companies, or is it just a generator of innovation for others to scale?

Breaking the Cycle of Pain: Biodol’s Solution for the Opioid Crisis

Biodol Therapeutics is aiming to ease the burden of chronic pain for millions of patients around the globe. The company is developing a unique new drug with a dual function: a non-opioid standalone treatment for neuropathic pain or migraine, but also a combination therapy with opioids. By reversing opioid tolerance, Biodol’s compound eliminates the need for higher doses, making these powerful drugs safer and more effective at alleviating suffering.

Fund+ Portfolio Company Tubulis to be Acquired by Gilead

• Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments • Tubulis’ next-generation ADC platform includes its clinically validated linker-payload technology • The acquisition includes Tubulis’ lead asset TUB-040, a NaPi2b-targeting ADC for ovarian cancer and other solid tumors

From Copycat to Top Dog: China is Becoming a Biopharma Powerhouse

With the rapid rise of Chinese biopharma, this ‘new kid on the block’ has gone from baby to behemoth on the world stage. This powerhouse of innovation and industry is now turning heads in both the US and Europe, having transformed from copycat to top dog in the space of just a few years. How has China done it, and what can Europe do in response?

R&D Real Estate: A Cornerstone of European Innovation

The most visible — yet often overlooked — parts of an innovative ecosystem are the buildings that house research and development activities. Far more than just office space, these physical foundations facilitate the translation of lofty ideas into tangible solutions for society. Kadans Science Partner is one of Europe’s foremost providers of this specialized infrastructure, with a unique community-minded model.

Health Innovation Funding: Spearhead Clusters Lead the Way in Flanders

BioVox spoke with Sara Van Overmeire and Annie Renders of Flanders Innovation & Entrepreneurship (VLAIO) about the origin and role of spearhead clusters. VLAIO is the Flemish government’s point of contact for all entrepreneurs in Flanders. It relies on Biovia and other spearhead clusters to bring companies together and support them in setting up innovative projects.

MeSH Counter: A Tool to Track Biomedical Research Trends

Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.

Belgian Biotech Agomab Debuts on Nasdaq with a $200 Million IPO

Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.

Hospitals and Belgian Companies Unite to Shape the Future of Healthcare

On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.

Dengue: A Virus Without Borders

We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.

Mind Over Money: US vs. European Investment Psychology in Biotech

Early-stage biotech investing has always demanded a high tolerance for uncertainty, and an uncanny ability to predict which fledgling technologies will one day reshape health. But one silent force shapes investment outcomes more often than we admit: psychology. At the intersection of capital and culture, we find a compelling and underexplored story — the differences between investors in the US and Europe, and how these contrasts play out in biotech.

To PhD or Not to PhD: A Growing Question in the Life Sciences

An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?

European Biotech Act: New initiative to mobilize €10 billion investment for Europe’s biotech sector

The European Commission and the European Investment Bank (EIB) Group have announced an initiative to mobilize €10 billion in investment in 2026-27 into the biotech and life sciences sector. The project aims to give a significant boost to the EU's competitiveness in biotechnology, by addressing the EU's current investment gap and mobilizing public-private investment into promising new health solutions.

Celebrating the Pitch Winners of HealthTech Investor Summit 2025

Europe’s healthtech pipeline was on full display at the HealthTech Investor Summit 2025 in Utrecht, with the regions brightest rising stars in the spotlight. From surgical robotics and implantable devices to bioelectronics and next-generation diagnostics, here are the pitching companies that stood out to both the judges and audience.